Treatment of Low-risk Prostate Cancer with Radical Hypofractionated Accelerated Radiotherapy with Cytoprotection (HypoARC): An Interim Analysis of Toxicity and Efficacy
Anticancer Research, 05/31/2011
Koukourakis MI et al.– The results show that hypofractionated Accelerated Radiotherapy with Cytoprotection (HypoARC) is feasible and safe for patients with low–risk prostate cancer and, considering also the high efficacy noted, a strong rationale is provided for the further evaluation of HypoARC in randomized trials.



